BostonGene

The AI engine Fit Assessment

Beta

BostonGene Corporation develops advanced biomedical software that utilizes AI for personalized therapy decision-making in cancer treatment, focusing on individual patient profiles and tumor characteristics. Their solutions include comprehensive molecular and immune profiling to optimize treatment options for patients.

Blurb

BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.

HQ Location

Waltham (United States)

Founded

2015

Employees

201 - 500

Total funding raised

$200.00M

Funding Status

Series B, $150.00M, April 6, 2022
Subspaces
  • Drug Repurposing

BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients.